BeOne Medicines (BEIGF) Other Working Capital Changes (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Other Working Capital Changes data on file, last reported at -$15.3 million in Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at -$15.3 million, up 48.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.5 million (up 150.12% YoY), and the FY2025 annual result was -$3.0 million, down 126.45% from the prior year.
• Other Working Capital Changes eased to -$15.3 million in Q1 2026 per BEIGF's latest filing, from $52.3 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $90.2 million in Q3 2023 and troughed at -$80.3 million in Q2 2022.
• A 5-year average of -$235941.2 and a median of $3.5 million in 2022 frame the typical range for Other Working Capital Changes.
• The sharpest annual moves came in 2022 and 2023: Other Working Capital Changes surged 1568.31% in 2022, then plunged 1033.01% in 2023.
• A 5-year view of Other Working Capital Changes shows it stood at $39.4 million in 2022, then plunged by 159.93% to -$23.6 million in 2023, then jumped by 187.59% to $20.7 million in 2024, then soared by 153.02% to $52.3 million in 2025, then plunged by 129.2% to -$15.3 million in 2026.
• Business Quant data shows BEIGF's Other Working Capital Changes at -$15.3 million in Q1 2026, $52.3 million in Q4 2025, and -$70.4 million in Q3 2025.